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ABSTRACT
Tumor necrosis factor superfamily member 14 (TNFSF14), LIGHT, is a component of the cytokine network that regulates innate and
adaptive immune responses, which promote homeostasis of lymphoid organs, liver, and bone. Metastatic tumors often disrupt
the tissuemicroenvironment, thus altering the homeostasis of the invaded organ; however, the underlyingmechanisms required fur-
ther studies. We investigated the role of LIGHT in osteolytic bone disease induced by metastatic non-small cell lung cancer (NSCLC).
Patients diagnosed with NSCLC bone metastasis show significantly higher levels of LIGHT expressed in monocytes compared with
non-bonemetastatic tumors and healthy controls. Serum LIGHT levels were also higher in patients with bonemetastases than in con-
trols, suggesting a role for LIGHT in stimulating osteoclast precursors. In bone metastatic patients, we also detected increased RNA
expression and serum RANKL levels, thus by adding anti-LIGHT or RANK–fragment crystallizable region (RANK-Fc) in PBMC cultures,
a significant inhibition of osteoclastogenesis was observed. To model this observation in mice, we used the mouse lung cancer cell
line LLC-1. After intratibial implantation, wild-type mice showed an increased number of osteoclasts but reduced numbers of osteo-
blasts and decreased osteoid formation. In contrast, Tnfsf14−/− mice showed no significant bone loss or other changes in bone
homeostasis associated with this model. These data indicate LIGHT is a key control mechanism for regulating bone homeostasis dur-
ing metastatic invasion. Thus, LIGHT may be a novel therapeutic target in osteolytic bone metastases. © 2019 American Society for
Bone and Mineral Research.
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Introduction
Lung cancer represents the primary cause of cancer-relatedmortality worldwide.(1) The predominant form of lung cancer
is non-small cell lung cancer (NSCLC), which metastasizes to bone
in 30% to 40% of patients, resulting in a very poor prognosis and
median survival time measured in months following lesion detec-
tion.(2) NSCLC bone metastases are mainly osteolytic and dramati-
cally impact patients’ quality of life, causing morbidity and having
substantial financial implications for healthcare providers.(3) In
order to develop innovative strategies to inhibit metastatic tumors,
we need to identify molecules that regulate bone metastasis.
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Cancer stem cells have been revealed to play an important role in
initiating the metastatic process(4) due to their interaction with the
bonemicroenvironment and immune system.(5) Indeed, the role of
the immune system in promoting NSCLC bone metastases has
been reported.(6) Among the immune mediators of bone metasta-
ses, the immunostimulatory cytokine, LIGHT, a member of TNF
superfamily (TNFSF14), may be relevant.(7,8) LIGHT is homologous
to lymphotoxins and engages the herpes virus entry mediator
(HVEM) and the Lymphotoxin-β receptor. LIGHT is produced by
immune cells, particularly by activated T-cells, monocytes, natural
killers, and neutrophils. It has been reported that LIGHT is involved
in increased bone resorption activity typical of the bone dis-
eases,(9,12) such as erosive rheumatoid arthritis(9) (RA) and multiple
myeloma.(9,12) LIGHT synergizes with RANKL to stimulate
osteoclastogenesis(10–12) and alternately inhibits osteoblastogen-
esis in myeloma,(12) thus suggesting that high LIGHT levels are
harmful for bone. Recently, a study usingmice genetically deficient
in LIGHT (Tnfsf14−/−) showed cancellous bone loss, indicating that
LIGHT mediates bone homeostasis.(13) Additional evidence has
shown that LIGHT expression in T cells and B cells impacts bone
homeostasis through the reduced expression of osteoprotegerin
(OPG) with consequent increased osteoclastogenesis, thus identi-
fying amechanism that contributes to the interplay between bone
and the immune system.(13) Given this evidence in bone homeo-




Peripheral blood (PB) samples were obtained from 61 newly diag-
nosed NSCLC patients (37 without bone metastases and 24 with
bone metastases) and 13 healthy donors. The patients’ characteris-
tics are reported in Supplementary Table 1. Patients signed
informed consent according to theDeclaration of Helsinki andwere
approved by the Comitato Etico Interaziendale of A.O.U. Città della
Salute e della Scienza di Torino – A.O. Ordine Mauriziano A.S.L. TO1
and of A.O.U. San Luigi Gonzaga di Orbassano.
Flow cytometry analysis
Peripheral blood mononuclear cells (PBMCs) were isolated from
PB samples andwere stainedwith the following conjugated anti-
bodies: phycoerythrin (PE) Light (R&D Systems, Inc., Minneapolis,
MN, USA), FITC-CD14 (Millipore, Billerica, MA, USA), FITC-CD25,
allophycocyanin (APC)-CD4 (Caltag Medsystems, Buckingham,
UK), APC-CD8 (GenWay Biotech, San Diego, CA, USA), peridinin-
chlorophyll-protein complex (PerCP)-CD16 (BioLegend, San
Diego, CA, USA). Unstained samples and isotypic control anti-
bodies PE, FITC, APC, and PerCP-Mouse IgG1, PE-IgG2a
(BioLegend; and Miltenyi Biotec, Bergisch Gladbach, Germany)
were used as negative controls. Samples were analyzed by flow
cytometry with FACs Calibur (Becton Dickinson, Franklin Lakes,
NJ, USA) and Flowlogic software (Miltenyi Biotec).
Osteoclastogenesis
PBMCs were isolated after centrifugation over a density gradient
using the Ficoll method. PBMCs were plated in 96-well plates at
5 × 105 cell/well, using Alpha-Minimal Essential Medium
(α-MEM, supplied by Invitrogen, Carlsbad, CA, USA), supplemen-
ted with 10% fetal bovine serum, benzylpenicillin (100 IU/mL)
and streptomycin (100 mg/mL) (Lonza, Basel, Switzerland) and
maintained at 37C in a humidified atmosphere of 5% CO2. To
obtain fully differentiated human osteoclasts (OCs), PBMCs from
patients with non-bone metastases were cultured in the pres-
ence or absence of recombinant human M-CSF (25 ng/mL) and
RANKL (30 ng/mL; PeproTech, Rocky Hill, NJ, USA) for 15 days.
PBMCs from patients with bone metastases were maintained in
α-MEM without any factors, because they spontaneously differ-
entiated into OCs, as described.(14) A neutralizing anti-LIGHT
mAb (R&D Systems, Inc.) was added in cultures at 100 and
500 ng/mL twice weekly. PBMCs were cultured in 96-well plates
(5 × 105 cells/well) in the presence of RANK–fragment crystalliz-
able region (RANK-Fc) at 20 ng/mL (PeproTech). At the end of the
culture period, cells were stained for tartrate-resistant acid phos-
phatase (TRAP; kit was supplied by Sigma-Aldrich, St. Louis, MO,
USA) and OCs were identified as TRAP-positive multinucleated
cells containing three or more nuclei.
Osteoblastogenesis
Primary human mesenchymal stem cells (MSCs) from human
exfoliated deciduous teeth (SHED), were obtained according to
the published procedure.(15) Cells were seeded in 24-well-plates
at 400/well, cultured alone or in co-cultures with PBMCs
(5.5 × 105 cell/well) in osteogenic differentiating medium, in
the absence or presence of 100 ng/mL anti-LIGHT mAb. At the
end of culture period (14 days), alkaline phosphatase (ALP) stain-
ing (ALP kit was supplied by Sigma-Aldrich) was performed and
the ALP-positive osteoblastic colony-forming units (CFU-OB)
were counted, as well as the relative percentage of CFU-OB to
the total culture area.
Real-time analysis
Total RNA was extracted by Trizol system (Invitrogen) from
patients’ PBMC samples, and 1 μg of RNA was converted into
single-stranded cDNA using the High-Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, Foster City, CA, USA).
Quantitative real-time PCR was carried out using SsoAdvanced
Universal SYBR Green Supermix and CFX96 system (Bio-Rad Lab-
oratories, Hercules, CA, USA). The mRNA expression of DcR3,
LTβR, HVEM, OPG, and RANKL was evaluated. The β-Actin gene
was used as the reference gene. Sequences of the probes and
primers were as published.(16)
ELISA
Patients’ sera were evaluated for the presence of circulating
LIGHT, OPG (R&D Systems, Inc.), and RANKL (BioVendor LLC,
Asheville, NC, USA), according to themanufacturer’s instructions.
The results were expressed as mean  SD.
Retrovirus preparation and cell transduction
Retroviruses were generated by transfecting the Pallino vector
expressing green fluorescent protein (GFP) in the 293GP packag-
ing cell line (Invitrogen). Transfected cells were incubated at
37C, and supernatants containing viral particles were collected
after 24 and 48 hours. For retroviral transduction, 300 μL filtered
retroviral supernatants was used to transduce 10 × 104 (1 × 105)
mouse Lewis lung carcinoma cell lines (LLC-1; purchased from
CLS Cell Lines Service GmbH, Eppelheim, Germany) plated on
six-well plates along with polybrene (8 μg/mL). After 12 hours
of incubation, 1 mL completemediumwas added, and cells were
cultured for an additional 48 hours. Transduced cells were then
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analyzed for GFP expression using a FACSCalibur flow cytometer
(Becton Dickinson). The CELLQuest software (Becton Dickinson)
was used for data acquisition and analysis.
Immunohistochemistry and histological analysis on
human bone biopsies
Immunohistochemistry was performed on 14 patients’ NSCLC
bone biopsies fixed in 10% neutral buffered formalin and decal-
cified with EDTA. These samples were kindly provided by Prof.
Papotti from the archive of the Department of Pathology of Città
della Salute e della Scienza di Torino. Tissues were embedded in
paraffin, and sections were deparaffinized, rehydrated through
graded alcohols, and subjected to antigen retrieval for immuno-
histochemistry. Sections were stained for H&E and polyclonal
anti-human LIGHT (Sigma-Aldrich; cat.n. HPA012700).
Mouse model
Tnfsf14 heterozygous mice were kindly provided by author CFW.
GFP-conjugated LLC1 (LLC1-GFP) cells were injected intratibially in
6-week-old, female WT and Tnfsf14−/− mice. In detail, mice were
anesthetized, and 1 × 104 LLC1-GFP cells in 50 μL PBS were
injected into the right tibia. PBS (50 μL) was injected into the left
tibia for an internal control, as reported in the literature.(17) Four to
five animals were housed in single cage at 23C on a light/dark
cycle and were fed a standard rodent chow. After 14 days mice
were euthanized and their tissues were surgically excised. Tibias
were fixed with 4% (vol/vol) paraformaldehyde for 18 hours at
4C and processed formicro–computed tomography (μCT) and his-
tological analysis. This animal interventional study is in accordance
with the European Law Implementation of Directive 2010/63/EU
and all experimental protocols were reviewed and approved by
the Veterinary Department of the Italian Ministry of Health.
μCT analysis of tibias
μCT scanning was used to measure morphological indices of
metaphyseal tibia regions. Tibias were rotated around their long
axes, and images were acquired using Bruker Skyscan 1172
(Kontich, Belgium) with the following parameters: pixel
size = 5 μm; peak tube potential = 59 kV; X-ray intensity = 167 μA;
0.4 rotation step. A set of three hydroxyapatite (HA) phantoms
were scanned and used for calibration to compute volumetric
BMD. For cortical bone properties, tibias were scanned at the
mid-diaphysis starting 5.5 mm from proximal tibial condyles
and extending for 200 6-μm slices (1.2 mm). For trabecular bone,
tibias were scanned starting at 1.9 mm from the proximal tibial
condyles, just distal to the growth plate, in the direction of the
metaphysis, and extending for 200 slices (1.2 mm).
Histological analysis
For evaluation of the tumor burden, mouse tibias were decalci-
fied and embedded with paraffin. Section were stained with
H&E and tumor burden was evaluated as the ratio of tumor area
on total area. Microphotographs were captured under a micro-
scope (Leica, Wetzlar, Germany) using a 10× objective lens and
analyzed using ImageJ software (NIH, Bethesda, MD, USA;
https://imagej.nih.gov/ij/).
For bone histomorphometry, tibias were embedded with
methylmethacrylate (MMA) and cut by a standard microtome
(RM2155; Leica, Heidelberg, Germany) into 5-μmslices for histology
as described.(13) For analysis of osteoclasts (OC number per bone
perimeter [N.Oc/B.Pm]), bone sections were incubated in TRAP
staining solution and then counterstained with methyl green; for
osteoblast analysis (OB number per bone perimeter [N.Ob/B.Pm]),
bone sections were stained with toluidine blue. Goldner’s Masson
trichrome stain was used to analyze new osteoid formation. Micro-
photographs were captured under a microscope (Leica) using a
40× objective lens and analyzed using ImageJ software.
Statistical analyses
Statistical analyses were performed by Student’s t test, nonpara-
metric tests (Mann-Whitney for not normal data), or ANOVA,
according to the Statistical Package for the Social Sciences soft-
ware (IBM SPSS, Armonk, NY, USA). Results were considered sta-
tistically significant at p < .05.
Results
Increased LIGHT expression in monocytes and serum from
patients with NSCLC bone metastases
Through flow cytometry, we analyzed LIGHT expression in CD4
and CD8 T cells, CD14 monocytes, and CD16 neutrophils from
58 of 61 NSCLC patients enrolled in the study: 22 patients with
and 36 without bone metastases, and 13 healthy donors. A signif-
icantly higher expression of LIGHT was detectable in monocytes
from bone metastatic patients compared with non-bone meta-
static NSCLC and healthy donors. (Fig. 1A–C). LIGHT expression
by monocytes was higher in patients with metastatic bone lesions
than in non-bone metastatic ones (66.5  24.5 versus 43.3  25.2,
p = .001), healthy donors (66.5  24.5 versus 8.5  4.6, p = .0002)
and in non-bone metastatic patients than in healthy donors
(43.3  25.2 versus 8.5  4.6, p = .0001) (Fig. 1D). Activated
CD4/CD25 T cells express higher levels of LIGHT compared to
CD8 T cells but were similar across all groups; no differences were
evident among the other cellular subsets. The mean values of
LIGHT expression among the different PBMC subpopulations is
reported in Supplementary Table 2. Serum LIGHT levels were also
significantly higher in bone metastatic patients than in non-bone
metastatic ones (186.8  191.2 pg/mL versus 115.8  73 pg/mL,
p = .04) and healthy donors (186.8  191.2 pg/mL veruss
85.7  38.4 pg/mL, p = .04) (Fig. 1E). Because LIGHT action is medi-
ated by the interaction with its receptors, lymphotoxin-β receptor
(LTβR), herpesvirus entry mediator (HVEM), and decoy receptor 3
(DcR3), we also evaluated their expression on patients’ PBMCs.
LTβR was not expressed, whereas HVEM and DcR3 expression
was not significantly different between bone and non-bone meta-
static patients (data not shown).
LIGHT expression in NSCLC bone metastases
In our series of bonemetastasis, careful routine histopathological
analysis showed atypical epithelial neoplastic cells morphologi-
cally consistent with NSCLC within hematopoietic tissue, without
evident malignant phenotype. In particular, we investigated the
expression of LIGHT in 14 NSCLC metastatic bone biopsies by
immunostaining. We found 8 of 14 tumor epithelial cell cases
expressed LIGHT, regardless the absence (Fig. 2A; ie, early phase
of bone marrow colonization) or presence of a reactive back-
ground, such as fibrous tissue (Fig. 2B) and osteosclerosis
(Fig. 2C). Notably, cytoplasmic staining of LIGHT was intermedi-
ate or strong in bonemetastases with no gland forming (ie, solid)
NSCLCs, whereas it was minimal or negative in NSCLCs
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associated with a gland-forming component (Fig. 2D). The LIGHT
expression was not detected in hematopoietic tissue.
LIGHT blockade inhibits osteoclastogenesis in vitro
As described,(6,14) OCs formed spontaneously in PBMC cultures
from bone metastatic patients, whereas cells from non-bone met-
astatic patients required M-CSF and RANKL. The number of OCs in
cultures from patients with bone metastases was significantly
higher than those fromnon-bonemetastatic cultures, even though
these ones received stimulating factors (272  98; 131  49,
p = .002), (Fig. 3A). A neutralizing mAb to LIGHT added to OC cul-
tures of both bone and non-bone metastases inhibited osteoclas-
togenesis, but the decrease was statistically significant only for
bone metastatic patients (272  98 versus 132  74, p = .01)
(Fig. 3B). The significant inhibition of osteoclastogenesis in bone
metastatic patients was also confirmed by TRAP staining (Fig. 3B).
In PBMC cultures from non-bone metastases, osteoclastogenesis
was only slightly reduced. Indeed, in these patients, LIGHT expres-
sionwas less than in bonemetastatic patients, suggesting that only
high levels of LIGHT can affect osteoclastogenesis in vitro.
RANKL and OPG in NSCLC patients
LIGHT synergizes with RANKL to induce osteoclastogenesis,(9,12)
and spontaneous osteoclastogenesis in bone metastatic patients
is regulated by RANKL.(6,14) The detection of higher LIGHT expres-
sion in patients with bone metastases suggests that the effect of
LIGHT on osteoclastogenesis might be due to a contribution from
RANKL. We found serum RANKL levels significantly higher in these
patients than in non-bonemetastatic ones (17.6  21.2 ng/mL ver-
sus 6.5  2.8 ng/mL, respectively). By contrast, serum OPG levels
were the same between the two groups (2  0.8 ng/mL versus
1.9  0.6 ng/mL, respectively). However, the RANKL/OPG ratio sig-
nificantly increased in patients with bonemetastases compared to
non-bone ones (8.9  10 ng/mL versus 6.8  7.2 ng/mL, respec-
tively, p = .04, Fig. 3C). After analyzing RANKL and OPG mRNA
expression in PBMCs, we found the same trend as for serum levels,
but the difference was not statistically significant (1.2  0.4 versus
0.9  0.3, respectively, Fig. 3D). The significant RANKL increase in
patients with bone compared to non-bone metastases prompted
us to test RANK-Fc on PBMC cultures frombonemetastatic patients
to demonstrate its ability to inhibit OC formation (Fig. 3E), thus sug-
gesting RANKL involvement in osteoclastogenesis.
Fig. 1. LIGHT expression in monocytes and serum from NSCLC patients. (A–C) Representative dot plots of CD14+/LIGHT+ monocytes from healthy donors and
patientswithout orwith bonemetastases are shown. (D) Significant increase of LIGHT expression onCD14+ cells derived frompatientswithout orwith bonemetas-
tases compared to healthy donors, and from patients with bone metastases compared to non-bone metastatic ones. (E) Increased serum LIGHT levels in patients
without and with bone metastases with respect to healthy donors. Comparison of multiple means was performed by one-way ANOVA; p values as shown.
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Blockade of LIGHT does not affect osteoblastogenesis
We investigated whether LIGHT mediates osteoblastogenesis in
co-cultures stimulated by NSCLC PBMCs, because it was revealed
to be able to inhibit CFU-OB formation in multiple myeloma.(12)
Although PBMCs stimulate MSC proliferation, LIGHT released
by PBMCs could interfere with CFU-OB, so we added anti-LIGHT
to counteract this potential inhibition. We performed co-cultures
Fig. 2. LIGHT expression in NSCLC bone metastases. LIGHT detected in tumor epithelial cells, regardless of the absence (A, D) or presence of a reactive
background, such as fibrous tissue (B) and osteosclerosis (C). (D) Cytoplasmic staining of LIGHT is minimal or negative in NSCLCs associated with a
gland-forming component. As it can be seen, in A andD it is also clear of hematopoietic tissue, whereas in B and C the carcinomatous infiltration is massive
without residual bone marrow. Photomicrographs on the right: original magnification ×100; photomicrographs on the left: original magnification ×200.
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of SHED-MSCs with PBMCs from patients with both bone and
non-bone metastases in osteogenic medium, with or without
100 ng/mL of anti-LIGHT mAb (Fig. 4). Anti-LIGHT did not affect
CFU-OB formation in co-cultures of patients with non-bone or
bone metastases, as shown by ALP staining (Fig. 4A,B, respec-
tively). We observed decreased CFU-OB formation in patients
with bone metastases compared to non-bone metastases, even
though the difference was not statistically significant (Fig. 4C).
These data support the known defect in OB formation and activ-
ity in the presence of osteolytic bone metastases.
Tnfsf14−/− mice injected with LLC1 are protected from
bone loss
To evaluate in vivo the effect of LIGHT neutralization, we
injected intratibial WT and Tnfsf14−/− (KO) mice with the
murine Lewis lung cancer cell line LLC-1. Interestingly, in tibias
the tumor burden, measured by histologic analysis showed a
slight reduction of tumor area in KO bones with respect to
WT mice (Fig. 5A-C). Furthermore, quantitative observations
of μCT-generated section images of tibias (Fig. 6) showed a sig-
nificant decrease in trabecular bone mass in injected WT mice
(WT-injected) compared to the vehicle WT mice (WT-vehicle)
(Fig. 6A,B). Interestingly, no significant differences were
observed between KO-injected mice and the KO-vehicle
(Fig. 6C,D), as well as for WT-injected versus KO-injected mice
(Fig. 6B–D), notwithstanding a reduction trend. In particular,
the WT-injected mice showed significantly reduced BV/TV, Tb.
N, Tb.Th, and Tb.Sp compared to the WT-vehicle mice
(Fig. 6E–H). Otherwise, these parameters did not show signifi-
cant variation in KO-injected mice toward the vehicle or in
WT-injected mice versus KO-injected mice. We consistently
found a significant increase in TRAP-stained OC number per
bone perimeter observed only in WT-injected mice versus the
WT-vehicle mice (Fig. 7A). Significantly, a slight decrease in
OB cell numbers was measured in WT-injected mice compared
Fig. 3. LIGHT and RANKL in the regulation of osteoclastogenesis in vitro. (A) Increased number of multinucleated (>3 nuclei), TRAP-positive OCs in bone
metastatic patients compared to non-bonemetastatic ones, and reduced OC number in bonemetastatic patients after anti-LIGHT treatment (500 ng/mL).
Comparison of multiple means was performed by one-way ANOVA. (B) Representative images of TRAP staining for OCs derived from bone metastatic
patients, in absence (CTRL) or presence of 100 and 500 ng/mL of anti-LIGHT. Increased RANKL/OPG ratio in patients with bone metastases compared
to non-bone ones (C); gene expression analysis, reported as RANKL/OPG ratio (D); significant reduction in osteoclastogenesis in PBMC cultures treated
with RANK-fc (20 ng/mL) (E). Two-tailed unpaired t tests were conducted for serum level and gene expression of RANKL/OPG, two-tailed paired t test
was conducted for RANK-fc experiments; p values as shown. Magnification ×10.
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to WT-vehicle mice (Fig. 7B). Otherwise, there were no signifi-
cant differences between KO-injected and KO-vehicle mice as
well as for WT-injected and KO-injected mice (Fig. 7B). Further-
more, a ~52% reduction in the area of osteoid surface to bone
surface (OS/BS) was observed inWT-injectedmice compared to the
WT-vehicle mice (p < .001), whereas in KO-injected mice, a slight
OS/BS% decrease was observed, not statistically significant com-
pared to the KO-vehicle mice (Fig. 7C). OS/BS% detected between
WT-injected and KO-injected mice did not show any significant dif-
ference (Fig. 7C). Overall, our data suggest that LIGHT deficiency
protects the loss of bone associated with LLC1 tumor cells.
Discussion
In this study, we showed for the first time that, in patients with
bone metastases from NSCLC, LIGHT expression increased in cir-
culating monocytes compared to patients without bone metas-
tases. Previously, it was reported that multiple myeloma
patients with bone disease showed an increased expression of
LIGHT in both CD14+ monocytes and CD16+ neutrophils,(12)
together with the role played by LIGHT in regulating osteoclasto-
genesis. Both NSCLC and multiple myeloma are characterized by
osteolytic bone disease, so increased LIGHT expression from
monocytes (which can differentiate into OCs) suggests that
LIGHT is also involved in the pathogenesis of osteolytic bone
metastases from NSCLC. During the analysis of LIGHT expression
in CD4+ and CD8+ T cells, as well as CD16+ neutrophils, we
found higher expression in CD4/CD25+ cells than CD8+ T cells,
although no difference was seen between bone and non-bone
metastatic patients. This suggests that LIGHT expressed in CD4
T cells could stimulate OC formation, as well as other factors
Fig. 4. LIGHTdoesnot affect osteoblastogenesis in co-culturesof SHED-MSCs
and patients’ PBMCs. Representative image of ALP staining for CFU-OB in co-
cultures of patients without bone metastases (A) and with bone metastases
(B), in absence or presence of 100 ng/mL anti-LIGHT neutralizing mAb. (C)
The mean number of CFU-OB/total area was not different in presence or
absence of anti-LIGHT for both bone and non-bonemetastatic patients. Data
arederived fromculturesof fournon-bonemetastaticpatients and threebone
metastatic ones. Two-tailed paired t tests were performed on both bone and
non-bonemetastatic groups; p values as shown. Magnification ×10.
Fig. 5. Tnfsf14−/−mice display decreased tumor burden in bone. Representative H&E-stained sections from WT (A) and KO (B) tibias injected with Lewis
lung carcinoma cell lines (LLC-1). (C) Graphs show calculated histologic analysis of tumor area/total bone area for WT and KO-injected mice, a slight
decrease in tumor area in KO bones respect to WT-mice was evident. Arrows point to tumor cells. The marked area represents the tumor area. n = 10 mice
per group. Two-tailed paired t tests were performed; p value as shown.
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(ie, IL-7, RANKL, TNF) released by CD4 T cells, known to promote
osteoclastogenesis.(18,19)
LIGHT production is reflected in the serum concentration;
indeed, it was significantly increased in NSCLC bone metastatic
patients, suggesting that LIGHT might regulate systemic osteoly-
sis by activating circulating OC precursors.
NSCLC bone biopsies showed distinctive LIGHT expression in
bone metastases. Specifically, the LIGHT staining in the samples
was markedly associated with less-differentiated cancer cells,
whereas only minimal or negative expression was detected
where intraosseous neoplastic cells were organized in a gland-
forming pattern, this being considered a histopathological detail
of nonaggressive behavior. This pattern of staining could reflect
the association of LIGHT bound to DcRe, a soluble receptor that
binds LIGHT, present in bone and other tissues, and secreted
by tumor cells.(20) Consequently, we advocated a new perspec-
tive in studying the role of LIGHT in NSCLC cells by considering
their differentiation status. In fact, as reported with reference to
a model of colon cancer, enforced LIGHT expression in tumor
cells triggered regression of established tumors and slowedmet-
astatic formation due to LIGHT stimulating an anti-tumor
response.(21,22) Our finding about the variation of LIGHT
expression, according to the differentiated status of NSCLC cells,
leads us to speculate that NSCLC cells may use a different ability
to escape the immune system.
We also confirm the role of LIGHT in sustaining OC formation
using an in vitro osteoclastogenesis assay based on patients’ PBMC
cultures. Specifically, a neutralizing anti-LIGHT antibody inhibited
osteoclastogenesis in PBMCs of patients with bone metastases,
whereas inPBMCcultures frompatientswithnon-bonemetastases,
osteoclastogenesiswas only slightly reduced. These results suggest
that patients without bonemetastases expressed LIGHT at physio-
logical levels, which did not affect osteoclastogenesis; namely, the
anti-LIGHT did not significantly inhibit OC formation. It has been
recently demonstrated that, physiologically, LIGHT interfered with
bone homeostasis protecting bone, while the absence of LIGHT
caused cancellous bone loss. Truly, LIGHT deficiency is associated
with pro-osteoclastogenic stimulation and increased OC bone
resorption.(13) To the same degree, elevated LIGHT levels in NSCLC
patients can activate osteolytic mechanisms, which is also a func-
tion of the RANK/RANKL/OPG axis.(6) Here, we show that adding
RANK-Fc to PBMC cultures significantly inhibited osteoclastogen-
esis in NSCLC patients with bonemetastases, suggesting that both
RANKL and LIGHT contribute to bone disease.
Fig. 6. Tnfsf14−/− mice injected with LLC1 are protected from bone loss. (A–D) Representative μCT-generated section images of trabecular bone in tibias har-
vested fromWT and Tnfsf14−/−mice, previously injectedwith vehicle or Lewis lung carcinoma cell lines (LLC-1). (E–H) Graphs show calculated trabecular param-
eters at the metaphysis of WT and Tnfsf14−/− mice. Trabecular bone parameters included BV/TV, Tb.Th, Tb.N, and Tb.Sp. The WT-injected mice displayed
significantly reduced BV/TV, Tb.N, Tb.Th, and Tb.Sp compared to theWT-vehicle mice. These parameters did not show significant variation for KO-injectedmice
with respect to the vehicle or for WT-injected mice versus KO-injected mice. n = 10mice per group. Comparison of multiple means was performed by one-way
ANOVA; p values as shown. BV/TV = bone volume/total volume; Tb.Th = trabecular thickness; Tb.N = trabecular number; Tb.Sp = trabecular separation.
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In basal conditions, osteoclastogenesis is mainly regulated by
the RANKL/OPG ratio. Here, in our cohort of NSCLC bone meta-
static patients, we observed high LIGHT levels and an unbalanced
RANKL/OPG ratio in favor of RANKL. Indeed, patients with bone
metastases had higher levels of RANKL than non-bone metastatic
ones, whereas OPG levels were comparable between the two
groups. LIGHT-KO mice also showed an unbalanced RANKL/OPG
ratio, due to OPG variations, while RANKL levels did not differ.(13)
In patients with osteolytic bone disease as well as in multiple mye-
loma patients,(23) we detected both high levels of RANKL and
LIGHT, which upregulated osteoclastogenesis. Conversely, in
Tnfsf14−/− mice, OPG increased, but the result was always an
unbalanced RANKL/OPG ratio associated with an upregulation of
osteoclastogenesis.(13) These data corroborate a fundamental role
of LIGHT in the maintenance of skeletal physiology, because its
dysregulation causes abnormal osteoclastogenesis.
To study the potential effects of LIGHT on osteoblastogen-
esis, we co-cultured SHED-derived MSCs and patient PBMCs
in the presence or absence of anti-LIGHT antibody. By contrast
to LIGHT KO mice and multiple myeloma, we observed no sig-
nificant LIGHT effect on osteoblastogenesis. We also found
decreased CFU-OB formation in patients with bone metastases
compared to non-bone ones. Despite this difference not statis-
tically significant, the results support the known defect in OB
Fig. 7. LIGHT stimulates osteoclastogenesis and inhibits osteoblastogenesis in vivo. Representative images of tartrate-resistant acid phosphatase–stained
osteoclasts in tibia sections from WT and Tnfsf14−/− mice, injected with vehicle or Lewis lung carcinoma cell lines (LLC-1), together with N.Oc/B.Pm. (A) A
significant increase in OC number was observed only in WT-injected mice compared to the WT-vehicle mice. (B) Toluidine blue–stained osteoblasts in
tibial sections from the samemice together with N.Ob/B.Pm. A slight but significant decrease in OB cell numbers was measured in WT-injectedmice com-
pared to WT-vehicle. (C) Representative images of Goldner’s Masson trichrome–stained tibia sections, together with measurement of percentage of oste-
oid per BS. A significant reduction was observed only inWT-injectedmice compared to theWT vehiclemice. n = 6mice per group. Comparison of multiple
means was performed by one-way ANOVA; p values as shown. Magnification ×40. N.Oc/B.Pm = OC number per bone perimeter; N.Ob/B.Pm = OB number
per bone perimeter; BS = bone surface.
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formation and activity in the presence of osteolytic bone
metastases.(5)
The mouse NSCLC-bone disease model revealed that the tumor
burden was reduced in KO bones compared to WT mice. Further-
more, LIGHT deficiency prevented significant decrease in bone
mass, whereas increased osteoclastogenesis and decreased osteo-
blastogenesis occurred inWTmice. Osteoid formationwas also sig-
nificantly reduced only in tumor-bearing WT mice, whereas KO
mice showed only a slight reduction, suggesting a key role for
LIGHT in causing bone disease in metastatic patients. In KO-LLC1
injected mice, the reduced bone disease may occur because of
the decreased tumor burden compared to WT-injected mice. Nev-
ertheless, we cannot exclude that the absence of further bone loss
with tumor injection in KOmice might depend on the already low
bonemass, associatedwith the LIGHT KO phenotype. A similar sce-
nario has been described for another co-stimulatory cytokine,
CD40L; indeed, mice lacking CD40L do not sustain the acute bone
loss triggered by estrogen deficiency.(24)
We reported that Tnfsf14−/−mice showed a reduced trabecular
bonemass compared to WTmice as well as high levels of LIGHT in
different pathologies with osteolytic bone disease, such asmultiple
myeloma,(12,23) alkaptonuria,(25) chronic kidney disease, and hemo-
dialysis in patients.(26) Moreover, Edwards and colleagues(9) mea-
sured increased LIGHT levels in erosive rheumatoid arthritis, thus
sustaining its central role in pathological bone remodeling.
In conclusion, the accumulated evidence supports a key role of
LIGHT in pathological bone remodeling and suggests that neutral-
izingLIGHTactivity could improvebone loss inpatientswithNSCLC.
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